Skip to content
Governance Register

← US public companies

Engene Therapeutics Inc.

SEC CIK 1980845 · ENGN · last insider filing 2026-06-17

Directors (from insider filings)

NameCapacity as filedFilings
Zoth Lota S. Director filed 2023 - 2026
Hastings Paul J Director filed 2024 - 2026
Glickman Richard M Director filed 2023 - 2026
Astley-Sparke Philip Director filed 2025 - 2026
Brunk Gerald A Director filed 2023 - 2026
Heffernan Michael Thomas Director filed 2025 - 2026
Grossman William Director · Interim Chief Medical Officer filed 2025 - 2026
Joustra Wouter Director filed 2024 - 2026
Cooper Ronald Harold Wilfred Director · Chief Executive Officer filed 2024 - 2026
Bos Jasper Director filed 2023 - 2025
Hanson Jason David Director · Chief Executive Officer filed 2023 - 2023

Officers (from insider filings)

NameTitle as filedFilings
Daws D. Ryan Chief Financial Officer filed 2023 - 2026
Buck Jill Chief Development Officer filed 2025 - 2026
Giguere Lee Chief Legal Ofc. and Corp Secy filed 2024 - 2026
Cheung Anthony Tzeyew Chief Technology Officer filed 2023 - 2026
Nichols Alexander Julian Pres. & Chief Operating Ofc. filed 2023 - 2026
Connolly Joan Chief Technology Officer filed 2024 - 2026
Boyd Matthew Ross Chief Regulatory Officer filed 2025 - 2026
Sweiti Hussein Chief Medical Officer filed 2025 - 2025
Pott Amy Chief Global Comm. Ofc. filed 2025 - 2025
Pruthi Raj Som Chief Medical Officer filed 2024 - 2025
Bryce Richard Paul Chief Medical Officer filed 2023 - 2023
Sullivan James Crowley Chief Scientific Officer filed 2023 - 2023
Grassin Alexandre Jean-Rene Erwan Int. Chief Financial Officer filed 2023 - 2023

About this record

From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.

Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.